Although there are many choices for the treatment of GC patients, including surgery, chemotherapy, radiation therapy, and targeted therapy, the prognosis of GC patients is still unsatisfactory.[4–6] Inspiringly, rapid progress in the development of immune checkpoint inhibitors, such as those targeting CTLA-4, PD-1 and PD-L1, may offer new hope for the treatment of GC patients. Here, CTLA4 is linked to gastric cancer.